The complex interaction between pathophysiologic features of OSA and OSA metabolic comorbidities seemed to modulate the variability in GAPDH/PRDX2 redox–oligomeric responses following PAP treatment among patients. Here, PRDX2 is linked to obstructive sleep apnea syndrome.